Compare Levi Strauss & Co. (LEVI) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Health Care Select Sector SPDR Fund — how do they compare? Levi Strauss & Co. trades at $24.55 (market cap $9.21B), while Health Care Select Sector SPDR Fund trades at $160.19. The key difference: Levi Strauss & Co. pays a 2.68% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| LEVI | XLV | |
|---|---|---|
Market Cap | $9.21B | — |
Sector | Consumer Cyclical | — |
52-Week High | $24.99 | $164.48 |
52-Week Low | $17.92 | $129.01 |
Enterprise Value | $10.52B | — |
Dividend Yield | 2.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss & Co. (LEVI) trades at $24.56, up 0.82% on the day, with strong analyst support (83% Buy rating) and a consensus price target of $28.00. Recent quarterly earnings have consistently beaten expectations, including a Q2 2026 EPS of $0.28 versus $0.24 expected, driven by robust direct-to-consumer growth. The company maintains solid profitability with a 61.72% gross margin and 9.66% net margin, while technical indicators show a bearish overall signal despite bullish moving averages.
The outlook is positive given earnings momentum and raised full-year guidance, though near-term stock performance faces headwinds from tariff concerns and foreign exchange pressures. Investment appeal lies in its digital strategy execution and dividend growth, with risks including competitive pressures and macroeconomic volatility affecting consumer spending.
XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.
XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
